AMX0035, developed by Amylyx Pharma out of Cambridge, is the first ALS treatment to come out of FDA Phase II trials that has been shown to slow or halt the progression of ALS as well as passing other criteria such as efficacy and limited side effects. The Michelle Gargaro Foundation is committed to providing assistance in any way they can to securing approval of AMX0035 with the FDA. We have pledged up to $5,000.00 towards the FDA approval of the use of AMX0035 for ALS patients. Please research AMX0035 on our website, or on the internet and support the effort. Contact us if you have any questions.
